CGEMのROE（自己資本利益率）は？

Cullinan Oncology LLCのROEは-60.36%です。

CGEMの配当利回りは？

Cullinan Oncology LLCの配当利回りは0.00%です。

CGEMの品質スコア（Quality Score）は？

当社のAIはCGEMの総合財務品質を100点中8点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。

CGEMは今が買い時ですか？

当社AIのタイミングスコアは100点中69点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。

CGEMはどのセクターに属しますか？

Cullinan Oncology LLCはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）

CGEM (NASDAQ) 株価分析 | CULLINAN ONCOLOGY LLC

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

CGEM AI Analysis Summary

Our AI summary for CGEM: Cullinan Oncology LLC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -60.36%, a dividend yield of 0.00%. Its financial Quality Score stands at 8/100 — fundamentals below the market average. The AI Timing Score is 69/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

CGEM

Cullinan Oncology LLC

US:NASDAQ STOCK Healthcare >> Biotechnology News 92

USD 16.50

-1.02 (-5.82%) Day Change

Watchlist Portfolio Compare Chart

0.00

D/E

-60.4%

ROE

-54.9%

ROA

0.00%

Div Yield

CULLINAN ONCOLOGY LLC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 16.50 Price -1.02 (-5.82%) Day Change	NEWS SCORE: 92

CGEM, ファンダメンタルスコアはnot good ( ファンダメンタル = 8) そしてテクニカルスコアは ...(Sign In to See)...

Loading chart...

8 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
ROAがROEに比べて低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Deepscope 分析

39%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	92
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	16.50
PBV / Sector	2.94 / 5.20
Earning Per Share	-3.39

PE / Sector	N/A / 19.97
PEG or PE/Growth / Sector	N/A / 1.22
Average 1M Daily Value	9.94 M
Average 1W Daily Value	10.06 M GREAT

Timing Factors

28%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

ポイントになる統計

37%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 98.71
NPM Average (%) / Sector	N/A / -1,721.76
NPM Change Average (%) / Sector	N/A / 5,211.62
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-54.85 / 27.02
ROA Average (%) / Sector	-28.52 / -368.17
ROA Change Average (%) / Sector	-45.12 / 5,404.12
ROE (%) / Sector	-60.36 / 3.47
ROE Average (%) / Sector	-31.10 / 6.51
ROE Change Average (%) / Sector	-44.12 / 2,128.13
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

配当

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

登録情報

Analyze Date	2026-08-01 07:59:38
Symbol	CGEM
Name	CULLINAN ONCOLOGY LLC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	61.46 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	1,076.75 / 9,903.94

ニュース

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: One Main Street, Cambridge, MA, United States, 02142

Phone: 617 410 4650

Website: https://cullinantherapeutics.com

Employees: 109

Sector: Healthcare >> Biotechnology

Description: Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.